A new protein-based treatment for triple-negative breast cancer
A Wholly Protein-based Self-assembly Nanoplatform for TNBC-specific Combination Therapy
This study is testing a new treatment called ProNano that uses tiny proteins to deliver medicine directly to triple-negative breast cancer cells, aiming to make the treatment more effective and less harmful than regular chemotherapy for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11079461 on NIH RePORTER |
What this research studies
This research focuses on developing a novel protein-based nanoplatform called ProNano, specifically designed to target and treat triple-negative breast cancer (TNBC). The approach involves creating a nanocore that can deliver therapeutic agents directly to TNBC cells by recognizing specific surface antigens. By combining tumor-targeting and therapeutic features, this platform aims to improve treatment efficacy while reducing the toxicity associated with traditional chemotherapy. Patients may benefit from a more effective and less harmful treatment option tailored to their cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer that express estrogen receptors, progesterone receptors, or HER2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a targeted and less toxic treatment option for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in using targeted nanoplatforms for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Liu, Rihe — Univ of North Carolina Chapel Hill
- Study coordinator: Liu, Rihe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.